A phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2109-2114

  Ramanathan, Ramesh K ^a,b   Kirkpatrick, D Lynn ^c   Belani, Chandra P ^a,b   Friedland, David ^a,b   Green, Sylvan B ^d   Chow, H H Sherry ^d   Cordova, Catherine A ^d   Stratton, Steven P ^d   Shadow, Elizabeth R ^c   Baker, Amanda ^d   Dragovich, Tomislav ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c ProlX Pharmaceutical Corp   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPROPYL 2 IMIDAZOLYL DISULFIDE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PX 12; STEROID; THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APPENDIX CANCER; ARTICLE; CANCER GROWTH; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; GROIN RASH; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPOXIA; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OXYGEN THERAPY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RIGOR; SARCOMA; SIDE EFFECT; SOLID TUMOR; TASTE DISORDER; THORAX PAIN; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; THIOREDOXIN;

EID: 34247507112     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2250     Document Type: Article

References (22)

1. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001;30:421-55.
2. Kirkpatrick DL, Ehrmantraut G, Stettner S, Kunkel M, Powis G. Redox active disulfides: the thioredoxin system as a drug target. Oncol Res 1997;9:3516.
3. Gromer S, Urig S, Becker K. The thioredoxin system - from science to clinic. Med Res Rev 2004;24:40-89.
4. Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 1997,57:5162-7.
5. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000;31:475-81.
6. Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.
7. Nakamura H, Bai J, Nishinaka Y, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000;24:53-60.
8. Kawahara N, Tanaka T, Yokomizo A, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996;56:5330-3.
9. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996;16:3459-66.
10. Oblong JE, Berggren M, Gasdaska PY, Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem 1994;269:11714-20.
11. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994;1218:292-6.
12. Powis G, Oblong JE, Gasdaska PY, Berggren M, Hill SR, Kirkpatrick DL. The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol Res 1994;6:539-44.
13. Yokomizo A, Ono M, Nanri H, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995;55:4293-6.
14. Sasada T, Iwata S, Sato N, et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 1996;97:2268-76.
15. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.
16. Kirkpatrick DL, Kuperus M, Dowdeswell M, et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998;55:987-94.
17. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatriack DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
18. ProlX Pharmaceuticals PX-12 Clinical Investigators Brochure 2005.
19. Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Hashash A, Kirkpatrick DL, Egorin MJ, Block LH, Lazo JS. Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2- imidazolyldisulfide. J Chromatogr B Analyt Technol Biomed Life Sci 2002;768:239-46.
21. 0.1 reactions with sulfides and thiols. Int J Mass Spectrom Ion Process 1998;172:149-59.
22. Baker AF, Dragovich T, Tate WR, et al. The antitumor thioredixon-1 PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 2006;147:83-90.